Overview
Despite serious safety concerns, germanium is used for cancer, heart disease, hepatitis, glaucoma, and other conditions. But there is no good scientific evidence to support these or other uses.
How does it work ?
Uses & Effectiveness ?
Insufficient Evidence for
- Cancer. Researchers are interested in spirogermanium, a form of germanium, as an alternative treatment for various kinds of cancer. But early research has shown only minimal response to treatment with spirogermanium. Other early research suggests that taking propagermanium, another form of germanium, by mouth for 1-7 months might benefit people with multiple myeloma, a type of blood cancer.
- Hepatitis B. Early research suggests that taking a specific product (Serocion, Yamanouchi, Japan) containing propagermanium by mouth for 16 weeks reduces the amount of active hepatitis virus in people with hepatitis B.
- A group of eye disorders that can lead to vision loss (glaucoma).
- Cataracts.
- Depression.
- Fatigue.
- Food allergies.
- Heavy metal poisoning.
- Heart disease.
- High blood pressure.
- High cholesterol.
- HIV/AIDS.
- Osteoarthritis.
- Pain.
- Swelling (inflammation) of the liver (hepatitis).Yeast infections.
- Viral infections.
- Weak and brittle bones (osteoporosis).
- Other conditions.
Side Effects
Organic forms of germanium are POSSIBLY UNSAFE when taken by mouth. Spirogermanium and propagermanium are examples of organic forms of germanium. These forms can build up in the body and cause serious side effects including kidney failure, multi-organ dysfunction, lung toxicity, and nerve damage.
Inorganic (elemental) germanium is LIKELY UNSAFE. This includes certain compounds such as germanium oxide. There have been more than 30 reports of kidney failure and death linked with use of these forms of germanium. It builds up in the body and can damage vital organs such as the kidneys. It can also cause anemia, muscle weakness, nerve problems, and other side effects.
When given by IV: Organic forms of germanium are POSSIBLY UNSAFE when injected intravenously (by IV). Spirogermanium and propagermanium are examples of organic forms of germanium. These forms can build up in the body and cause serious side effects including kidney failure, multi-organ dysfunction, lung toxicity, and nerve damage.
Special Precautions and Warnings
Interactions ?
Furosemide (Lasix) interacts with GERMANIUM
Some scientists think that germanium might decrease how well furosemide (Lasix) works. But there isn't enough information to know if this is a big concern.
Minor Interaction
Be watchful with this combination
Dosing
Asaka T, Nitta E, Makifuchi T, et al. Germanium intoxication with sensory ataxia. J Neurol Sci 1995;130:220-3.. View abstract.
Aso, H., Suzuki, F., Yamaguchi, T., Hayashi, Y., Ebina, T., and Ishida, N. Induction of interferon and activation of NK cells and macrophages in mice by oral administration of Ge-132, an organic germanium compound. Microbiol.Immunol. 1985;29(1):65-74. View abstract.
Budman DR, Schulman P, Vinciguerra V, Degnan TJ. Phase I trial of spirogermanium given by infusion in a multiple-dose schedule. Cancer Treat Rep 1982;66:173-5.. View abstract.
Cho JM, Chae J, Jeong SR, Moon MJ, Shin DY, Lee JH. Immune activation of Bio-Germanium in a randomized, double-blind, placebo-controlled clinical trial with 130 human subjects: Therapeutic opportunities from new insights. PLoS One. 2020 Oct 19;15(10):e0240358. View abstract.
DiMartino, M. J., Lee, J. C., Badger, A. M., Muirhead, K. A., Mirabelli, C. K., and Hanna, N. Antiarthritic and immunoregulatory activity of spirogermanium. J Pharmacol Exp.Ther. 1986;236(1):103-110. View abstract.
Ettinger DS, Finkelstein DM, Donehower RC, et al. Phase II study of N-methylformamide, spirogermanium, and 4-demethoxydaunorubicin in the treatment of non-small cell lung cancer (EST 3583): an Eastern Cooperative Oncology Group study. Med Pediatr Oncol 1989;17:197-201.. View abstract.
Fujimoto, M., Ishibashi, H., Shimamura, R., Takahashi, K., Hirata, Y., Kudo, J., Niho, Y., Kira, J., and Miyata, K. [A patient with liver cirrhosis manifesting various symptoms including cerebellar ataxia due to germanium intoxication]. Fukuoka Igaku Zasshi 1992;83(3):139-143. View abstract.
Gerber GB, Leonard A. Mutagenicity, carcinogenicity and teratogenicity of germanium compounds. Mutat Res 1997;387:141-6.. View abstract.
Goodman S. Therapeutic effects of organic germanium. Med Hypotheses 1988;26:207-15.. View abstract.
Hess B, Raisin J, Zimmermann A, et al. Tubulointerstitial nephropathy persisting 20 months after discontinuation of chronic intake of germanium lactate citrate. Am J Kidney Dis 1993;21:548-52.. View abstract.
Higuchi I, Izumo S, Kuriyama M, et al. Germanium myopathy: clinical and experimental pathological studies. Acta Neuropathol (Berl) 1989;79:300-4.. View abstract.
Hirayama, C., Suzuki, H., Ito, M., Okumura, M., and Oda, T. Propagermanium: a nonspecific immune modulator for chronic hepatitis B. J Gastroenterol. 2003;38(6):525-532. View abstract.
https://www.accessdata.fda.gov/cms_ia/importalert_139.html. Accessed Jan. 7, 2019
Iijima, M., Mugishima, M., Takeuchi, M., Uchiyama, S., Kobayashi, I., and Maruyama, S. [A case of inorganic germanium poisoning with peripheral and cranial neuropathy, myopathy and autonomic dysfunction]. No To Shinkei 1990;42(9):851-856. View abstract.
Jao, S. W., Lee, W., and Ho, Y. S. Effect of germanium on 1,2-dimethylhydrazine-induced intestinal cancer in rats. Dis.Colon Rectum 1990;33(2):99-104. View abstract.
Kamijo, M., Yagihashi, S., Kida, K., Narita, S., and Nakata, F. [An autopsy case of chronic germanium intoxication presenting peripheral neuropathy, spinal ataxia, and chronic renal failure]. Rinsho Shinkeigaku 1991;31(2):191-196. View abstract.
Kaplan, B. J., Parish, W. W., Andrus, G. M., Simpson, J. S., and Field, C. J. Germane facts about germanium sesquioxide: I. Chemistry and anticancer properties. J.Altern.Complement Med. 2004;10(2):337-344. View abstract.
Krapf R, Schaffner T, Iten PX. Abuse of germanium associated with fatal lactic acidosis. Nephron 1992;62:351-6.. View abstract.
Kumano, N., Ishikawa, T., Koinumaru, S., Kikumoto, T., Suzuki, S., Nakai, Y., and Konno, K. Antitumor effect of the organogermanium compound Ge-132 on the Lewis lung carcinoma (3LL) in C57BL/6 (B6) mice. Tohoku J Exp.Med. 1985;146(1):97-104. View abstract.
Kuwabara, M., Ohba, S., and Yukawa, M. Effect of germanium, poly-trans-[2-carboxyethyl] germasesquioxane on natural killer (NK) activity in dogs. J Vet.Med.Sci. 2002;64(8):719-721. View abstract.
Lin CH, Chen TJ, Hsieh YL, et al. Kinetics of germanium dioxide in rats. Toxicology 1999;132:147-53.. View abstract.
Long, Q. C., Zeng, G. X., and Zhao, X. L. Pharmacokinetics of germanium after po beta-carboxyethylgermanium sesquioxide in 24 Chinese volunteers. Zhongguo Yao Li Xue.Bao. 1996;17(5):415-418. View abstract.
Luck BE, Mann H, Melzer H, et al. Renal and other organ failure caused by germanium intoxication. Nephrol Dial Transplant 1999;14:2464-8.
Luck, B. E., Mann, H., Melzer, H., Dunemann, L., and Begerow, J. Renal and other organ failure caused by germanium intoxication. Nephrol.Dial.Transplant. 1999;14(10):2464-2468. View abstract.
Mainwaring MG, Poor C, Zander DS, Harman E. Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide. Chest 2000;117:591-3.. View abstract.
Matsusaka T, Fujii M, Nakano T, et al. Germanium-induced nephropathy: report of two cases and review of the literature. Clin Nephrol 1988;30:341-5.. View abstract.
Mrema, J. E., Slavik, M., and Davis, J. Spirogermanium: a new drug with antimalarial activity against chloroquine-resistant Plasmodium falciparum. Int.J Clin.Pharmacol Ther.Toxicol. 1983;21(4):167-171. View abstract.
Nagata, N., Yoneyama, T., Yanagida, K., Ushio, K., Yanagihara, S., Matsubara, O., and Eishi, Y. Accumulation of germanium in the tissues of a long-term user of germanium preparation died of acute renal failure. J.Toxicol.Sci. 1985;10(4):333-341. View abstract.
Nakada, Y., Kosaka, T., Kuwabara, M., Tanaka, S., Sato, K., and Koide, F. Effects of 2-carboxythylgerumanium sesquioxide (Ge-132) as an immunological modifier of post-surgical immunosuppression in dogs. J Vet.Med.Sci. 1993;55(5):795-799. View abstract.
Obara, K., Saito, T., Sato, H., Yamakage, K., Watanabe, T., Kakizawa, M., Tsukamoto, T., Kobayashi, K., Hongo, M., and Yoshinaga, K. Germanium poisoning: clinical symptoms and renal damage caused by long-term intake of germanium. Jpn.J.Med. 1991;30(1):67-72. View abstract.
Peng X, Lingxia Z, Schrauzer GN, Xiong G. Selenium, boron, and germanium deficiency in the etiology of Kashin-Beck disease. Biol Trace Elem Res 2000;77:193-7.. View abstract.
Pronai, L. and Arimori, S. Protective effect of carboxyethylgermanium sesquioxide (Ge-132) on superoxide generation by 60Co-irradiated leukocytes. Biotherapy 1991;3(3):273-279. View abstract.
Raisin, J., Hess, B., Blatter, M., Zimmermann, A., Descoeudres, C., Horber, F. F., and Jaeger, P. [Toxicity of an organic Germanium compound: deleterious consequences of a "natural remedy"]. Schweiz.Med.Wochenschr. 1-8-1992;122(1-2):11-13. View abstract.
Sanai T, Okuda S, Onoyama K, et al. Germanium dioxide-induced nephropathy: a new type of renal disease. Nephron. 1990;54:53-60.. View abstract.
Schauss AG. Nephrotoxicity and neurotoxicity in humans from organogermanium compounds and germanium dioxide. Biol Trace Elem Res 1991;29:267-80.. View abstract.
Schauss, A. G. Nephrotoxicity in humans by the ultratrace element germanium. Ren Fail. 1991;13(1):1-4. View abstract.
Schein PS, Slavik M, Smythe T, et al. Phase I clinical trial of spirogermanium. Cancer Treat Rep 1980;64:1051-6.. View abstract.
Takeuchi A, Yoshizawa N, Oshima S, et al. Nephrotoxicity of germanium compounds: report of a case and review of the literature. Nephron 1992;60:436-42.. View abstract.
Tao SH, Bolger PM. Hazard assessment of germanium supplements. Regul Toxicol Pharmacol 1997;25:211-9. View abstract.
Tao SH, Bolger, PM. Hazard assessment of germanium supplements. Regul Toxicol Pharmacol 1997;25:211-9. View abstract.
Trope C, Mattsson W, Gynning I, et al. Phase II study of spirogermanium in advanced ovarian malignancy. Cancer Treat Rep 1981;65:119-20.. View abstract.
Tsutsumi, Y., Tanaka, J., Kanamori, H., Musashi, M., Minami, H., Fukushima, A., Yamato, H., Ehira, N., Kawamura, T., Obara, S., Ogura, N., Asaka, M., Imamura, M., and Masauzi, N. Effectiveness of propagermanium treatment in multiple myeloma patients. Eur.J Haematol. 2004;73(6):397-401. View abstract.
Van der Spoel, J. I., Stricker, B. H., Schipper, M. E., de Bruijn, W., de Smet, P. A., and Esseveld, M. R. [Toxic damage of kidney, liver and muscle attributed to the administration of germanium-lactate-citrate]. Ned.Tijdschr.Geneeskd. 6-22-1991;135(25):1134-1137. View abstract.
Vogelzang NJ, Gesme DH, Kennedy BJ. A phase II study of spirogermanium in advanced human malignancy. Am J Clin Oncol 1985;8:341-4.. View abstract.
Wada T, Hanyu T, Nozaki K, et al. Antioxidant activity of Ge-132, a synthetic organic germanium, on cultured mammalian cells. Biol Pharm Bull. 2018;41(5):749-753. View abstract.
Wang L, Zheng C, Zhao D. Successful management of germanium poisoning-induced multiple organ dysfunctions by combined blood purification therapy. Curr Med Res Opin. 2020 Apr;36(4):687-691. View abstract.
Woolley, P. V., Ahlgren, J. D., Byrne, P. J., Priego, V. M., and Schein, P. S. A Phase I trial of spirogermanium administered on a continuous infusion schedule. Invest New Drugs 1984;2(3):305-309. View abstract.
Yanagisawa H, Yamazaki N, Sato G, Wada O. L-Arginine treatment may prevent tubulointerstitial nephropathy caused by germanium dioxide. Kidney Int 2000;57:2275-84.. View abstract.
Yang MK, Kim YG. Protective role of germanium-132 against paraquat-induced oxidative stress in the livers of senescence-accelerated mice. J Toxicol Environ Health A 1999;58:289-97.. View abstract.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.